Canakinumab (Ilaris) subcutaneous injection — Medical Necessity and Prior Authorization Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Medical necessity and prior authorization criteria for canakinumab (Ilaris) subcutaneous injection administered by a healthcare professional for approved autoinflammatory and inflammatory indications, governing providers and members covered by Blue Cross NC.
For CAPS: Added required diagnostic confirmation by either genetic testing or presence of elevated inflammatory markers plus at least two CAPS-typical symptoms.
For TRAPS: Added required diagnostic confirmation by genetic testing; added requirement for chronic or recurrent disease (>6 flares per year) and submission of baseline CRP levels.
For HIDS/MKD: Combined criteria; added diagnostic confirmation by genetic testing or significantly elevated serum IgD, requirement for at least 3 febrile episodes in 6 months, and baseline CRP submission.
For FMF: Added required diagnostic confirmation by genetic testing, requirement for active disease (≥1 febrile episode per month), and baseline CRP submission.
For SJIA and AOSD: Allowed continuation of canakinumab for patients established on an FDA-approved biologic or systemic immunomodulator if they have had positive clinical benefit; added defined trial durations for conventional agents for AOSD to align with SJIA.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.